Early inductive events in mammalian nephrogenesis depend on an interaction between the ureteric bud and the metanephric mesenchyme. However, mounting evidence points towards an involvement of additional cell types--such as stromal cells and angioblasts--in growth and patterning of the nephron. In this study, through analysis of the stem cell factor (SCF)/c-kit ligand receptor pair, we describe an additional distinct cell population in the early developing kidney. While SCF is restricted to the ureteric bud, c-kit-positive cells are located within the renal interstitium, but are negative for Foxd1, an established marker of stromal cells. In fact, the c-kit-positive domain is continuous with a central mesodermal cell mass ventral and lateral to the dorsal aorta, while Foxd1-expressing stromal cells are continuous with a dorsal perisomitic cell population suggesting distinct intraembryonic origins for these cell types. A subset of c-kit-positive cells expresses Flk-1 and podocalyxin, suggesting that this cell population includes angioblasts and their progenitors. c-kit activation is not required for the survival of these cells in vivo, because white spotting (c-kit(W/W)) mice, carrying a natural inactivating mutation of c-kit, display normal intrarenal distribution of the c-kit-positive cells at E13.5. In addition, early kidney development in these mutants is preserved up to the stage when anemia compromises global embryonic development. In contrast, under defined conditions in organ cultures of metanephric kidneys, c-kit-positive cells, including the Flk-1-positive subset, undergo apoptosis after treatment with STI-571, an inhibitor of c-kit tyrosine phosphorylation. This is associated with reductions in ureteric bud branching and nephron number. Conversely, exogenous SCF expands the c-kit-positive population, including Flk-1-positive angioblasts, and accelerates kidney development in vitro. These data suggest that ureteric bud-derived SCF elicits growth-promoting effects in the metanephric kidney by expanding one or more components of the interstitial c-kit-positive progenitor pool.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ydbio.2006.07.026DOI Listing

Publication Analysis

Top Keywords

c-kit-positive cells
16
ureteric bud
12
stromal cells
12
cell population
12
developing kidney
8
cells
8
kidney development
8
including flk-1-positive
8
cell
7
c-kit-positive
7

Similar Publications

Cell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state.

Stem Cell Res Ther

November 2024

Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, 391 Technology Way, Winston-Salem, NC, 27101, USA.

Article Synopsis
  • Congenital heart defects can cause right ventricular (RV) pressure overload, leading to heart failure, prompting research into cell-based therapies like mesenchymal stromal cells (MSCs) and c-kit positive cells (CPCs) for restoring function.
  • In a study, juvenile rats underwent pulmonary artery banding to induce RV pressure overload, followed by the injection of different cell types, with results analyzed using advanced protein profiling techniques.
  • The findings showed that MSC therapy significantly reversed changes in RV proteins caused by pressure overload, outperforming other cell types, indicating the potential effectiveness of these therapies in cardiac recovery.
View Article and Find Full Text PDF

Extrarenal rhabdoid tumors (ERRTs) are highly aggressive pediatric tumors with very few cases reported in the literature. These tumors, similar to their renal counterparts, are characterized by inactivating mutations of the SMARCB1/INI-1 gene, a member of the SWI/SNF chromatin remodeling pathway. Diagnosis of ERRTs appears challenging owing to its rarity, varied morphological profile with a higher tendency for rhabdoid differentiation, and overlapping features with other SMARCB-1 deficient tumors.

View Article and Find Full Text PDF

Background: Congenital heart defects can lead to right ventricular (RV) pressure-overload and heart failure. Cell-based therapies, including mesenchymal stromal cells (MSCs) and c-kit positive cells (CPCs) have been studied clinically as options to restore heart function in disease states. Many studies have indicated these cells act through paracrine mechanisms to prevent apoptosis, promote cellular function, and regulate gene/protein expression.

View Article and Find Full Text PDF

Primate-Specific DAZ Regulates Translation of Cell Proliferation-Related mRNAs and is Essential for Maintenance of Spermatogonia.

Adv Sci (Weinh)

August 2024

Department of Andrology, Center for Men's Health, Urologic Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.

Primate-specific DAZ (deleted in azoospermia) has evolved in the azoospermia factor c (AZFc) locus on the Y chromosome. Loss of DAZ is associated with azoospermia in patients with deletion of the AZFc region (AZFc_del). However, the molecular mechanisms of DAZ in spermatogenesis remain uncertain.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists wanted to see if a special mixture called MTHSWD, combined with heart cells from a lab, could help mice with heart damage feel better.
  • They tested this on mice with heart problems and found that the treatment improved their heart function and reduced damage.
  • The study showed that this combo helped the heart cells survive and grow, activating more healing cells in the heart and increasing important growth factors.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!